Trial Search Results

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype (GT) 1b, 4 and 6 hepatitic C virus (HCV)-infected participants.

Part C of this study is designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir, simeprevir, TMC647055 and ritonavir (RTV) when administered in combination with or without RBV for 12 weeks in treatment-naïve or interferon/RBV-treatment relapsed, GT 1a and 1b HCV-infected participants.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Merck Sharp & Dohme LLC

Collaborator: Janssen Research & Development, LLC

Stanford Investigator(s):


  • Drug: Samatasvir
  • Drug: Simeprevir
  • Drug: Ribavirin (RBV)
  • Drug: TMC647055
  • Drug: Ritonavir (RTV)
  • Biological: Pegylated interferon (Peg-IFN)
  • Other: Samatasvir matching placebo


Phase 2


Inclusion Criteria:

   - Must have Genotype 1a, 1b, 4 or 6 HCV infection.

   - Documented clinical history compatible with chronic hepatitis C

   - HCV treatment-naïve or interferon/RBV-treatment relapsed (Part C)

   - Must agree to use an acceptable double method of birth control (one of which must be a
   barrier method) for at least 6 months after the last dose of study drugs.

Exclusion Criteria:

   - Female participants who are pregnant or breastfeeding.

   - Body Mass Index (BMI) > 36 kg/m2.

   - Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).

   - History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.

   - History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
   encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
   hypertension or hepatic insufficiency.

   - Has one or more known primary or secondary causes of liver disease, other than
   hepatitis C

   - History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins,
   non-HCV viral hepatitis, gallstones or other etiologies

   - Donated blood or had significant blood loss 30 days prior to dosing

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting